Birchview Capital, LP Aptinyx Inc. Transaction History

Birchview Capital, LP

  • $108 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 01, 2018
SELL
$20.21 - $31.85 $202,100 - $318,500
-10,000 Closed
0 $0
Q2 2018

Aug 02, 2018
BUY
$19.83 - $24.17 $198,299 - $241,700
10,000 New
10,000 $242,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Birchview Capital, LP Portfolio

Follow Birchview Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Birchview Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Birchview Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email